rifaximin

/Tag:rifaximin

Abstract Number: 395

RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence in adults and may be used in combination with lactulose. Practice guidelines state that rifaximin [...]

By | 2019-03-11T14:25:21-04:00 March 11th, 2019|Hospital Medicine 2019, Research, Transitions of Care|Comments Off on RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS

Abstract Number: 228

RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin 550 mg tablets is a nonsystemic antibiotic indicated for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults and may be used alone or in combination with the cathartic lactulose. This [...]

By | 2019-03-11T14:21:17-04:00 March 11th, 2019|Hospital Medicine 2019, Patient Safety, Research|Comments Off on RIFAXIMIN ALONE VERSUS RIFAXIMIN AND LACTULOSE COMBINATION THERAPY FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: SAFETY PROFILE IN PATIENTS WITH CIRRHOSIS

HM2018 Abstract Number: 331

PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

Background: Rifaximin, a nonsystemic antibiotic, may be used alone or in combination with lactulose for reducing the risk of overt hepatic encephalopathy (OHE) recurrence in adults. This analysis evaluated rifaximin alone and rifaximin + lactulose [...]

By | 2018-03-19T15:44:00-04:00 March 19th, 2018|Research, Transitions of Care, Uncategorized|Comments Off on PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE WITH RIFAXIMIN ALONE VERSUS RIFAXIMIN PLUS LACTULOSE THERAPY: IMPACT ON QUALITY OF LIFE AND CAREGIVER BURDEN IN PATIENTS WITH CIRRHOSIS

HM2018 Abstract Number: 359

ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN

Background: Hepatic encephalopathy (HE) is a common neurological complication in patients with cirrhosis. In addition to numerous morbidity-related issues, HE is associated with substantial economic burden. Treatment includes lactulose or rifaximin, a nonsystemic antibiotic that [...]

By | 2018-03-19T12:52:34-04:00 March 19th, 2018|Hospital Medicine 2018, Research, Value in Hospital Medicine|Comments Off on ECONOMIC BURDEN OF OVERT HEPATIC ENCEPHALOPATHY AND PHARMACOECONOMIC IMPACT OF RIFAXIMIN